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Context: Autosomal-recessive mutations in the growth hormone receptor (GHR) are the most common
causes for primary growth hormone insensitivity (GHI) syndrome with classical GHI phenotypically
characterized by severe short stature and marked insulin-like growth factor (IGF)-I deficiency. We
report three families with dominant-negative heterozygousmutations in the intracellular domain of the
GHR causing a nonclassical GHI phenotype.
Objective: To determine if the identified GHR heterozygous variants exert potential dominant-
negative effects and are the cause for the GHI phenotype in our patients.
Results: All three mutations (c.964dupG, c.920_921insTCTCAAAGATTACA, and c.945+2T.C) are
predicted to result in frameshift and early protein termination. In vitro functional analysis of variants
c.964dupG and c.920_921insTCTCAAAGATTACA (c.920_921ins14) suggests that these variants are
expressed as truncated proteins and, when coexpressed with wild-type GHR, mimicking the hetero-
zygous state in our patients, exert dominant-negative effects. Additionally, we provide evidence that a
combination therapy of recombinant human growth hormone (rhGH) and rhIGF-I improved linear
growth to within normal range for one of our previously reported patients with a characterized,
dominant-negative GHR (c.899dupC) mutation.
Conclusion: Dominant-negative GHR mutations are causal of the mild GHI with substantial growth
failure observed in our patients. Heterozygous defects in the intracellular domain of GHR should,
therefore, be considered in cases of idiopathic short stature and IGF-I deficiency. Combination therapy
of rhGH and rhIGF-I improved growth in one of our patients.
Abbreviations: ALS, acid labile subunit; cDNA, complementary DNA; GH, growth hormone; GHBP, growth hormone binding
protein; GHI, growth hormone insensitivity; GHR, growth hormone receptor; hGHR, human growth hormone receptor; IGF,
insulin-like growth factor; JAK2, Janus-family tyrosine kinase 2; mRNA, messenger RNA; P, patient; rhGH, recombinant
human growth hormone; RT-PCR, reverse transcription polymerase chain reaction; SD, standard deviation; STAT5B, signal
transducer and activator of transcription 5B; TBST, tris(hydroxymethyl)aminomethane-buffered saline with Tween 20; WT,
wild-type.
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The human growth hormone (GH) receptor (GHR) mediates the growth and metabolic effects of
GH through a cascade of downstream signaling leading to the transcription of multiple genes,
including insulin-like growth factor (IGF)-I. The GHR consists of an extracellular domain that
binds GH, a short transmembrane domain, and an intracellular domain involved in transducing
signals uponbinding ofGH.The receptor lacks intrinsic kinase activity and recruits Janus-family
tyrosine kinase 2 (JAK2) for activation of downstream signaling. Binding of GH to the dimeric
cell-surface receptor induces conformational changes in the receptor resulting in trans-
phosphorylation of the associated JAK2 [1]. Phosphorylated JAK2, in turn, phosphorylates the
seven intracellular tyrosine residues of GHR, including those that are critical for activation of the
signal transducer and activator of transcription 5B (STAT5B) in humans [2]. Phosphorylated
STAT5B dimerizes, translocates to the nucleus, and regulates the transcription of target genes,
including IGF1, IGFBP3, and IGFALS [3–5].
Mutations ofGHR (MIM 600946) are the most common cause for primary GH insensitivity
(GHI) syndrome, phenotypically characterized by severe short stature [heights as low as210
standard deviations (SDs) below normal], dysmorphic facial features, and marked IGF-I
deficiency. To date, more than 80 different mutations in GHR have been identified in more
than 300 case reports [6–9]. The overwhelming majority of the reported mutations are
autosomal-recessive (deletions, point or splice mutations) and are located in sequences
encoding the extracellular domain of the receptor [9]. Very few proven clinically important
heterozygous mutations in GHR have been reported, of which only four have been shown to
exert dominant-negative effects [10–15]. We now report the identification of three hetero-
zygous variants in the intracellular domain of the GHR in three unrelated patients who
present with postnatal growth failure, IGF deficiency, and a relatively normal facial phe-
notype. We demonstrate that these variants also exerted dominant-negative effects; im-
portantly, therapeutic options are available for these patients, and we show that long-term
treatment with a combination of recombinant human GH (rhGH) and rhIGF-I improved
linear growth to within the normal range for our previously described patient who carried the
GHR c.899dupC dominant-negative mutation.
1. Case Reports
Patient 1 (P1) is a girl initially evaluated at age 3 years, 4 months. Height was 84 cm (23.09
SD) and weight 11.3 kg (22.36 SD). She was born at 39 weeks of gestation with a weight of
3.5 kg (+0.23 SD) and length of 49.5 cm (20.29 SD). Her metabolic panel, complete blood
count, karyotype, celiac panel, and thyroid function tests were normal. She had a normal
serumGH level (4.3 ng/mL; normal,,10), low serum IGF-I level (,25 ng/mL; normal, 49 to 290)
and low normal IGF binding protein 3 (IGFBP-3) (1.1 mg/L; normal, 0.9 to 4.5). GH stimulation
testing showed a peak GH level of 14.1 ng/mL (after clonidine), 23.7 ng/mL (after arginine), and
24.7 ng/mL (after glucagon). During a subsequent evaluation at the age of 7 years, 6months, P1’s
physical examination revealed a small midface, mild frontal bossing, bluish sclerae, and delayed
dental age. An IGF-I generation test was performed after GH was given for a week. Baseline
IGF-Iwas 24ng/mL (normal, 39 to 198); afterGHstimulation, IGF-Iwas 44 ng/mL (normal, 39 to
198).Her basal IGFBP-3 levelwas 1.2mg/L (normal, 1.5 to 3.4), withno further increase afterGH
stimulation. She had normal values of acid labile subunit (ALS), ruling out ALS deficiency. Her
GH binding protein (GHBP) was mildly elevated at 1991 pmol/L (normal, 267 to 1638).
Her mother is of Hispanic ethnicity with normal height (157 cm, 20.98 SD) and had
menarche at 12 years of age. Her brother was of normal stature. Her father (Northern
European ethnicity) was modestly short [Fig. 1(a)] with a height of 161.5 cm (22.1 SD) and
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had delayed puberty (around 17 years of age). Short stature was prevalent on the father’s side
of the family. Her paternal grandmother’s height is 150 cm (22.07 SD); paternal great aunts,
142 cm (23.23 SD) and 150 cm (22.07 SD); and paternal great uncle, 145 cm (24.4 SD). The
height of the paternal uncle is normal (170 cm, 20.93 SD).
P1 was started on rhIGF-I therapy at the age of 8 years, 8months, with incremental dosing
over the course of 6 weeks to 120 mg/kg/dose twice daily. Her height at the start of rhIGF-I
treatmentwas109.9 cm (23.89SD)and, at theageof 9years, 6months,was116 cm(23.24SD).Her
annualized growth velocity on rhIGF-I improved to 8.1 cm/y compared with 4 cm/y before ther-
apy [Fig. 2(a)]. The family also reported increased energy andmuscle strength with treatment.
Patient 2 (P2) is a Spanish boy with a height of 88.8 cm (23.1 SD) and a weight of 11.3 kg
(22.0 SD) at age 3.8 years. He had normal thyroid function; serum IGF-I was low normal at
69 ng/mL (normal, 55 to 297). He was born at 37 weeks with weight of 2.6 kg (20.7 SD), birth
length of 48 cm (20.3 SD), and head circumference of 31.5 cm (21.2 SD). His body proportions
were normal and he had no dysmorphic features. At the age of 2 years, he was diagnosed with
celiac disease; his autoantibodies normalized with good adherence to diet.
Growth velocity was 4 to 6 cm per year with a bone age delayed at least 2.5 years. IGF-I
concentrations were repeatedly low. At age 6 years, P2 underwent a GH stimulation test
(clonidine); he had a peakGH response of 17.7mU/L. At age 9.6 years, P2 underwent an IGF-I
generation test with GH given for 5 days (0.35 mg/kg/d); it elicited a poor response. Baseline
IGF-I was ,25 ng/mL (normal, 55 to 297) and upon GH stimulation, IGF-I remained below
Figure 1. Heterozygous GHR variant segregation in affected families. (a) P1, c.964dupG; (b)
P2, c.920_921ins14; (c) P3, c.945+2T.C; and (d) P4, de novo c.899dupC [15]. Arrow, proband.
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normal (34 ng/mL; range, 55 to 297). Basal and stimulated IGFBP-3 levelswere 1.28mg/L and
1.99 mg/L, respectively (normal, 1.5 to 7.4).
The parents were not consanguineous and his father was of normal stature (164 cm;
21.8 SD). His mother was modestly short [Fig. 1(b)] with a height of 149.5 cm (22.46 SD).
rhGH treatment, started at 10.6 years (0.035 mg/kg/d), resulted in an increased growth
velocity to 8 cm/yea but IGF-I remained persistently low (maximumvalue, 87 ng/mL). At age
12 years, P2’s height was at22.5 SD, with bone age delayed by 1.5 years. He was noted to be
in puberty at 13.5 years (testes, 6mL and 8mL). At 14.5 years, low-dose rhIGF-I (40mg/kg/d)
was added to his treatment regimen. At 15 years (testes, 12mL), his height was 154 cm (22.02
SD), weight 38 kg (21.99 SD), and bone age 14.5 years [Fig. 2(b)].
Patient 3 (P3) was a 12-year-old Spanish girl from a nonconsanguineous marriage. She
presented with a substantially short stature (119.6 cm, 24.30 SD) and normal facial fea-
tures. She had a high basal GH (57.6 ng/mL), low IGF-I (43 ng/mL; normal, 126 to 1188 ng/mL),
low IGFBP-3 (0.87 mg/L; normal, 2.0 to 9.3), and low ALS (7.4 mg/L; normal, 14 to 29). Her
GHBP was elevated (35,634 pmol/L; normal, 534 to 5785). Further investigation revealed
the presence of a substantially short stature in three other family members [Fig. 1(c)]: the
patient’s father (150.5 cm, –3.6 SD), mother (138.6 cm, –4.3 SD), and maternal grandfather
(150 cm, –4.0 SD).
Figure 2. The growth charts of the patients carrying heterozygous GHR variants. (a) P1,
c.964dupG; (b) P2, c.920_921ins14; (c) P3, c.945+2T.C; and (d) P4, c.899dupC [15]. The time
frame of rhIGF-I, rhGH, and rhIGF-I + IGFBP3 treatments are indicated on the growth
curves. CDC, Centers for Disease Control and Prevention.
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The patient was started on a then-available combination therapy of rhIGF-I/rhIGFBP-3
(1mg/kg/d) at age 15, 1month aftermenarche. Treatmentwaswell tolerated but responsewas
poor, although only given for a total of 10 months at quite an advanced age. Her height at the
beginning of the treatment was 135 cm and at the end of treatment was 137.8 cm [Fig. 2(c)].
The treatment was discontinued at age 15 years, 10 months.
Patient 4 (P4), previously reported [15], had a height of 85.4 cm (24.17 SD) and weight of
11.4 kg (23.66 SD) at age 4.2 years, bone age of 3.0 years, normal GH and GHBP
concentrations, a low IGF-I of 16 ng/mL (normal, 54 to 178), and a low IGFBP-3 of 0.7 mg/L
(normal, 0.8 to 3.0). He carried a de novo, dominant-negative, heterozygous GHR c.899dupC
mutation [Fig. 1(d)] [10]. Treatment with rhIGF-I (120 mg/kg twice daily) was initiated, and
his pretreatment growth velocity of 4.2 cm/y (age, 4.2 years) improved to 8.0 cm/y after 1 year
of treatment, and height SDwas23.30 at age 5.3 years [15]. After 3 years of rhIGF-I therapy,
rhGH (0.28 mg/kg/wk) was added to the regimen and rhIGF-I dosing adjusted to 90 mg/kg/
dose, a combination that further increased growth velocity to.10 cm/y.When treatment with
rhIGF-I was interrupted for a year (because of unavailability of the drug), growth velocity
dropped to,7 cm/y while continuing rhGH therapy. The resumption of the coadministration
therapy (at age 10.75 years) increased growth velocity to.10 cm/year again [Fig. 2(d)], and at
age 11.25 years, his height was in the normal range (139.2 cm,20.81 SD). He was noted to be
in puberty at age 11.7 years (testicular volumes, 8mLbilaterally), with bone ages of 12.5 years
(phalanges) and 11.5 years (metacarpals).
The clinical, biochemical, and treatment profiles of all four patients are summarized in
Table 1.
2. Materials and Methods
A. Sample Procurement
Informed consent was obtained from the families to participate and provide samples (DNA,
whole blood, skin biopsy for establishing primary fibroblasts), in compliance with the In-
stitutional Review Board at Cincinnati Children’s Hospital Medical Center (Cincinnati,
Ohio), SIEMENS, and Seattle Children’s laboratory. Genomic DNA was isolated from pe-
ripheral blood of patients and their parents as previously described [15]. Whole exome se-
quencingwas performed onDNAsamples fromP1, her unaffected brother, and her parents, as
previously described [16]. For P2 and P3, targeted Sanger sequencing of the GHR coding
exons (NM_000163.4), exons 2 through 10, was performed, as previously described [15]. For
P3, total RNA was extracted from peripheral leukocytes and GHR messenger RNA (mRNA)
was amplified by reverse transcription polymerase chain reaction (RT-PCR) to determine
integrity of exon 9 splicing events.
B. Regenerating the GHR Variants for Functional Studies
The plasmid pcDNA carrying the full-length human GHR (kind gift from Dr. Richard Ross)
was used as template to regenerate variants c.964dupG and c.920_921ins14. The variants
were generated using the QuikChange II XL Site-DirectedMutagenesis Kit fromAgilent, as
previously described [10]. The c.920_921ins14 variant was generated in three sequential
steps. In the first two steps, five nucleotides were inserted; in the last step, four nucleotides
were inserted resulting in insertion of 14 nucleotides in total. The primers for the site-
directed mutagenesis were designed using the Quick change primer design program from
Agilent. The sequence of the primers used is shown in Table 2.
C. Cell Culture and Transfection
HEK293 cells weremaintained inDulbecco’smodifiedEaglemedium supplementedwith 10%
fetal bovine serum at 37°C in 5% CO2. For in vitro functional analyses, HEK293 cells were
transfected with the vector (pcDNA3.1), wild-type (WT), and/or the mutant GHR variants
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using Polyjet transfection reagent (SignaGen Laboratories). After 24 hours of transfection,
the cells were serum starved in Dulbecco’s modified Eagle medium supplemented with 0.1%
bovine serum albumin for 8 or 16 hours and then treated with rhGH as indicated. All
transfection experiments were performed at least three independent times.
D. Immunoblot Analysis
For immunoblot analyses, transfected cells were treated with 100 ng/mL rhGH for 20minutes;
cell lysates were prepared and processed as previously described [10]. Protein concentrations of
the lysates were determined by the Bradford assay and equal quantities of protein were loaded
onto a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel. After electropho-
resis, the proteins were transferred onto nitrocellulose membranes, blocked using 5% bovine
serum albumin or 5% nonfat milk in 1X tris(hydroxymethyl)aminomethane-buffered saline
Table 1. SummaryofClinical, Biochemical, andTreatmentProfiles ofPatientsWithDominant-Negative
Mutations in the GHR
P1 P2 P3 P4
c.964dupG/WT c.920_921ins14/WT c.945+2T>C/WT c.899dupC/p.R229H
Mutation Duplication Insertion Splicing Duplication
Age, y 3.4 3.8 12 4.2
Sex Female Male Female Male
Height, cm (SD) 84 (23.09) 88.8 (23.1) 119.6 (24.3) 85.4 (24.17)




Birth week 39 37 NA NA
Birth weight,
kg (SD)
3.56 (+0.23) 2.6 (20.7) NA 3.38
Birth length,
cm (SD)
49.5 (20.29) 48 (20.3) NA 48
Paternal height,
cm (SD)
161.5 (22.1) 164 (21.8) 150.5 (23.6) 180.3 (+0.48)
Maternal height,
cm (SD)




4.3 NA 56.6 8
GH stimulated 14.1 ng/mL
(clonidine)
17.7 mU/L (clonidine) NA 37 ng/mL (arginine)
IGF-I,
ng/mL (RR)
,25 (49–290) 69 (55–297) 43 (126–1188) 16 (54–178)
IGFBP-3,
mg/L (RR)
1.1 (0.9–4.5) NA 0.87 (2.0–9.3) 0.7 (0.8–3.0)
ALS,
mg/L (RR)
4.6 (2.3–11) NA 7.4 (14–29) 2.6 (1.9–10)
GHBP,
pmol/L (RR)
1991 (267–1638) NA 35,634 (534–5785) 1379 (267–1638)
Treatment
Treatment rhIGF-I rhGH rhGH + rhIGF-I rhIGF-I
+ rhIGFBP-3
rhIGF-I rhGH + rhIGF-I
Dose 120 mg/kg bid 0.035 mg/kg/d 0.035 mg/kg/d (rhGH)
+ 40 mg/kg/d
(rhIGF-I)
1 mg/kg/da 120 mg/kg bid 0.04 mg/kg/d (rhGH)
+ 90 mg/kg
bid (rhIGF-I)
Age, y 8.8 12.08 14.8b 15 4.7 11.7b
IGF-1,
ng/mL (RR)
206 (57–305) 87 (80–690) 309 (180–820) NA 211 (36–202) 326 (86–393)
IGFBP3,
mg/L (RR)
NA 3.4 (2.1–9.2) 3.73 (.3.1) NA 0.6 (1–4.7) 0.9 (2–4.8)
ALS,
mg/L (RR)
NA NA NA NA NA 3.3 (5.6–6)
Reference This study This study This study Aisenberg et al. (2010)
Derr et al. (2011), this study
Abbreviations: bid, twice daily; NA, not available; RR, reference range.
arhIGF-I + rhIGFBP3 combination therapy that is no longer available.
bTanner II-III, testes 8 mL.
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with Tween 20 (TBST) and incubated with the appropriate primary and secondary antibodies
(fluorescent-labeled or horseradish peroxidase–conjugated). Following incubation, the blots
probed with fluorescent-labeled secondary antibodies were washed in 1X TBST and mem-
branes were scanned using the Odyssey IR Imaging System (LICOR Biosciences). The blots
probed with the horseradish peroxidase–conjugated secondary antibodies were washed in 1X
TBST and developed using the super signal maximum sensitivity detection system (Thermo
Scientific, catalog no. 37075).
E. Luciferase Reporter Assays
HEK293 cells were transfected with a total input DNA of 2.0 mg, including 1 mg luciferase
(pGHRE-LUC) [10] and vector pcDNA3.1 or specified human GHR (hGHR) constructs (WT,
GHR c.964dupG, and c.920_921ins14) as indicated. After 24 hours of transfection, cells were
serum starved for ~8 hours and treated with 10 ng/mL rhGH for 18 hours. Cell lysates were
collected, and luciferase activitywasdeterminedusing the luciferaseassay system fromPromega
per manufacturers’ protocol. The assay was performed at least three independent times.
3. Results
A. Identification and Segregation of the GHR Variants
The clinical profiles of our patients who presented with progressive growth failure, normal or
high GH, and low IGF-I suggest that mutations in the GHR, or in components downstream of
the receptor, could be causal of their short stature. All three candidate variants subsequently
identified were in GHR and located in sequences encoding the intracellular domain of the
GHR [Fig. 3(a)]. Whole exome sequencing data from P1, her parents, and brother were
stringently filtered for autosomal dominant variants because the father was also short and
the parents were not known to be related. The top candidate was a heterozygous variant,
c.964dupG in exon 10 of GHR (NM_000163.4), which was confirmed by Sanger sequencing
[Fig. 3(b) and 3(c)] to cosegregate with the growth phenotype in the family [Fig. 1(a)]. For P2
and P3, targeted Sanger sequencing of GHR revealed a heterozygous insertion of 14 nu-
cleotides in exon 9 (c.920_921ins14) [Fig. 3(d) and 3(e)] and a heterozygous c.945+2T.C
(invariant dinucleotide of the donor splice site of intron 9) [Fig. 3(g) and Fig. 3(h)],
Table 2. Primers Used to Generate the Human GHR Variants, c.964dupG and c.920_921ins14
Primer Name Primer Sequence
Primers used to generate the hGHR c.964dupG variant
hGHR c.964dupG forward 50 GGAAGGAAAATTAGAGGAGGGTGAACACAATC
TTAGCCATT 30
hGHR c.964dupG reverse 50 AATGGCTAAGATTGTGTTCACCCTCCTCTAATTTT
CCTTCC 30
Primers used to generate the hGHR c.920_921ins14 variant
hGHR c.920_921ins14 (step 1) forward 50 CCCCAGTTCCAGTTCCAAAGATTAATCTCAAGGAA
TCGATCCA 30
hGHR c.920_921ins14 (step 1) reverse 50 TGGATCGATTCCTTGAGATTAATCTTTGGAACTGG
AACTGGGG 30
hGHR c.920_921ins14 (step 2) forward 50 CAGTTCCAGTTCCAAAGATTAATCTCAAAGATAGG
AATCGATCCAG 30
hGHR c.920_921ins14 (step 2) reverse 50 CTGGATCGATTCCTATCTTTGAGATTAATCTTTGG
AACTGGAACTG 30
hGHR c.920_921ins14 (step 3) forward 50CCAGTTCCAAAGATTAATCTCAAAGATTACAAGGA
ATCGATCCGATC 30
hGHR c.920_921ins14 (step 3) reverse 50 GATCTGGATCGATTCCTTGTAATCTTTGAGATTAA
TCTTTGGAACTGG 30
Nucleotides inserted are underlined.
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respectively. Each of these variants segregated appropriately with the growth phenotype in
the family [Fig. 1(a–c)]. Interestingly, the father of P3 who was also significantly short
statured, wasWT forGHR, and had serum IGF-I levels within the low normal range (93 ng/mL;
reference range, 90 to 360); the molecular cause for his short stature remains unknown.
For variants c.964dupG and c.920_921ins14, the duplication of a nucleotide (c.964dupG) or
insertion of 14 nucleotides (c.920_921ins14) results in frameshift and predicted early protein
termination (p.V322Gfs*9 and p.K307Nfs*18, respectively). The c.945+2T.C variant is
predicted to destroy the donor splice site in intron 9 and would result in the splicing out of
exon 9, which encodes the Box1 region essential for JAK2 association. The absence of exon 9
was confirmed by RT-PCR amplification of the segment ofGHRmRNA sequences encoded by
exons 8 through 10 [Fig. 3(h) and 3(i)]. The amplified GHR complementary DNA (cDNA)
product produced a 187-bp band in the normal control sample and two bands (187 bp and
117 bp) in a sample from P3 [Fig. 3(h) and 3(i)]. Sequencing of the 117-bp fragment confirmed
the absence of exon 9 [Fig. 3(g)]. Skipping exon 9 would result in a frameshift, generation of
three amino acids, and a premature stop codon, p.I293Kfs*4.
B. Variants hGHR:c.964dupG and hGHR: c.920_921ins14 are Readily Expressed but Cannot
Activate GH-induced STAT5 Signaling
All three variants are predicted to result in truncation of the intracellular domain of theGHR,
with retained transmembrane domain sequences (amino acid residues 265 through 288)
presumed to permit anchoring of the truncated receptors to the membrane. The truncated
GHR peptides, if expressed, should also be capable of forming heterodimers with WT GHR,
possibly interfering with downstream signaling as have been described for our (and others)
previously identified dominant-negative GHR variants [10–12, 14]. For our c.945+2T.C
variant, the splicing out of exon 9 is identical to the two previously reported heterozygous
splicing defects (c.876-1G.C and c.945+1G.A), which also resulted in excision of exon 9 [12,
14]. Because loss of exon 9 generates a mature truncated protein of 277 amino acids that has
been already demonstrated to have dominant-negative effects when coexpressed with theWT
GHR [12, 14], we focused on functionally evaluating the GHR frameshift variants, c.964dupG
and c.920_921ins14. The regenerated variants were analyzed in reconstituted HEK293 cells.
In the homozygous state, both hGHR:c.964dupG and hGHR: c.920_921ins14 variants were
robustly expressed as truncated, ~65 kDa, peptides, and, as might be expected, failed to
activate STAT5B signaling in response to GH treatment [Fig. 4(a) and 4(b)] .
C. GH-Induced Phosphorylation of STAT5B and Transcriptional Activities are Significantly
Reduced When the Variants are Coexpressed With WT GHR
To determine whether the strongly expressed truncated hGHR variants could affect normal
functioning ofWT hGHR, each of the variants was cotransfected withWT hGHR in a 1:1 ratio
to mimic the heterozygous state seen in our patients. GH-induced STAT5B phosphorylation
was significantly reduced when either variant was coexpressed withWT hGHR [Fig. 4(a) and
4(b)]. To determine if the observed reduction in STAT5B phosphorylation had an effect onGH-
induced transcriptional activities, WT hGHR (0.5 mg) was cotransfected with increasing
concentrations of the hGHR variants, hGHR:c.964dupG or hGHR: c.920_921ins14 (0.25–0.5
mg), and the pGHRE-LUC reporter. Luciferase activities were significantly reduced when the
mutant was coexpressed with the WT GHR [Fig. 4(c)].
Altogether, our results support the hypothesis that the heterozygous mutants identified in
our patients exert dominant-negative effects.
4. Discussion
We report the identification of three heterozygous, dominant-negative GHR variants,
c.964dupG, c.920_921ins14, and c.945+2T.C, in three unrelated patients who present with
substantial postnatal growth retardation, partial GHI, and IGF-I deficiency. Our cases
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Figure 3. Heterozygous GHR variants identified in affected patients. (a) Schematic
representation of the hGHR protein showing the various domains and the location of the
heterozygous mutations, c.899dupC, c.920_921ins14, c.945+2T.C, and c.964dupG. TM,
transmembrane. (b) Electropherograms of the WT GHR and P1 carrying the c.964dupG
variant. The reverse primer was used for sequencing and the electropherogram presented is
the complement, forward sequences. Heterozygosity is, therefore, visualized 50 to the
highlighted G nucleotide. (c) DNA sequence (50 to 30) and corresponding amino acids showing
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increase the number of known dominant-negativeGHR defects to seven [11, 13–15], but such
mutationsmaybemuchmore prevalent because, in comparisonwith classical GHI, themilder
phenotype seen in affected patients may be difficult to diagnose. Indeed, such patients are
likely to be classified as having idiopathic short stature because they lack the phenotype
classically associated with autosomal-recessive GHR mutations. Of note, serum GHBP
concentrations were high normal, or even markedly elevated (P3), supporting in vivo ex-
pression of both normal and mutant GHR. Importantly, we provide evidence that a combi-
nation of rhGH and rhIGF-I appears to be a viable option for successful, longitudinal
treatment of such patients.
For our previously described patient carrying the heterozygous c.899dupC mutation (P4;
height SD,24.17), initial treatment with rhIGF-I had improved growth velocity (8 cm/y), but
the subsequent addition of rhGH to his treatment regimen further increased his growth
velocity to .10 cm/y, allowing his growth profile to reach the normal range [Fig. 2(d)]. In-
terestingly, during an interruption to his combination therapy (when only rhGH was
available), a reduction in his growth velocity was noted, further supporting the benefit of the
combination therapy approach (at least for this patient). Based on the successful combination
therapy for P4, P2 (carrying the c.920_921ins14mutation) is now being treated with a similar
combination treatment regimen, and, although growth has improved to near the normal
range, the true efficacy remains somewhat uncertain because the patient is also in puberty. It
is possible that the improved growth could be attributed to the pubertal state. P1 is currently
on rhIGF-I therapy only, which improved her growth velocity, as was observed initially for P4.
It remains to be determined if the addition of rhGH for P1 could be as helpful as for P4.
Although administration of rhIGF-I is the first treatment of choice for patients with GHI
and IGF deficiency, rhIGF-I will only transiently increase serum IGF-I and, through a
negative feedback mechanism, inhibit GH secretion and downstream signaling. On the other
hand, rhGH therapy, if patients are even partially responsive, such as P2 was, not only will
increase circulating IGF-I but also IGFBP-3 and ALS concentrations, which can prolong the
half-life of IGF-I. For P2, who was treated long-term with rhGH, serum IGF-I was only
modestly increased although serum IGFBP-3 was normalized (Table 1), and the addition of
rhIGF-I significantly increased serum IGF-I concentrations, as might be expected (Table 1).
For patient P4, whowas treated with a combination of rhGH and rhIGF-I, serum IGF-I was in
the upper range of normal but serum IGFBP-3, surprisingly, remain consistently below
normal, whereas serum ALS, which was normal before treatment, also did not increase as
might be expected (Table 1). These biochemistries suggested either a lack of response to
rhGH, or that rhIGF-I, through the negative feedback loop to the pituitary, inhibited sub-
sequent GH-induced signaling. Optimal growth velocities for P4, however, were observed
with the combination therapy, suggesting beneficial effects of including rhGH despite the
biochemistries. Altogether, our data, albeit limited, correlated normalized serum IGF-I
concentrations with improved growth in patients with dominant-negative GHR mutations.
Interestingly, a recent, 3-year, multicenter, open-label trial demonstrated that a combination
the duplication of the nucleotide G (underlined) in the c.964dupG variant and the resulting
frameshift and early termination (stop). (d) Electropherograms of the forward WT GHR and
P2 showing the c.920_921ins14 variant. (e) DNA sequence (50 to 30) and corresponding amino
acid sequence showing the insertion of 14 bp at nucleotide 921 of GHR cDNA (boxed) in the
c.920_921ins14 variant, the resulting frameshift, and stop. (f) Electropherograms of the exon
9–intron 9 junction from WT GHR and P3 carrying the c.945+2T.C variant (arrow); the
mother, but not the father, carried the variant, as did the maternal grandfather (data not
shown). (g) Schematic, c.945+2T.C splicing out of exon 9. *Position of the mutation. The
cDNA sequence and translated products of WT (GHR) and the c.945+2T.C variant are
shown (bottom) along with the splice junctions. (h) DNA gel of GHR mRNA RT-PCR products
from a normal control and P3, amplified using primers from exon 8 to 10. The expected
product size is 187 bp (control). The presence of a smaller 117-bp band in the proband
confirms deletion of exon 9. (i) A larger sample (20 mL) of the RT-PCR product better
demonstrates the presence of two products (187 bp and 117 bp) carried by P3.
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Figure 4. GH-induced STAT5B activities in HEK293 cells transiently transfected with the
WT and mutated GHR variants regenerated by site-directed mutagenesis. Input hGHR
constructs are indicated. The fully glycosylated GHR, truncated GHR, PAK STAT5 (pSTAT5),
and total STAT5B are indicated by arrows. (a) Immunoblot analysis of GHR, STAT5B, and
GH-induced STAT5B activation in cells transfected with the c.964dupG variant. (b)
Immunoblot analysis of GHR, STAT5B, and GH-induced STAT5B activation in cells
transfected with the c.920_921ins14 variant. (c) GH-induced transcriptional activities as
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therapy of rhGH/rhIGF-I also significantly augmented growth in children with short stature,
GH sufficiency and IGF-I deficiency [17]. Hence, for coadministration therapy approaches,
frequentmonitoring of IGF-I, IGFBP-3, and ALSmay be necessary to ensure that normalized
serum IGF-I has been achieved. Of note, rhGH and rhIGF-I currently need to be administered
via separate injections because the combined product has not been made available for
clinical use.
It is of note that one of our patients (P3, c.945+2T.C) had serum GHBP markedly ex-
ceeding the normal range. This was not observed in previously characterized patients who
carried similar GHR exon 9 splicing mutations [12, 14]. Serum GHBP levels up to 100-fold
above normal have been detected only in patients carrying heterozygous,GHR exon 8 splicing
mutations, as we had previously reported [18]. Loss of exon 8, which encodes the GHR
transmembrane domain, would result in truncated GHR unable to anchor to the cell surface
[18] and the higher than normal GHBP has been hypothesized to sequester endogenous
circulating GH, thereby reducing the availability of GH for binding to the GHR. However,
these patients had normal serum IGF-I, IGFBP-3, and ALS levels, suggesting one copy of WT
GHR may be sufficient for normal responsiveness to their elevated, endogenous GH [18],
although short staturewas still prevalent. For P3, although it remains unclearwhyher serum
GHBP was so high, her serum IGF-I, IGFBP-3, and ALS levels were well below the normal
ranges, suggesting an adequate proportion of expressed truncatedGHR is anchored and acted
in the predicted dominant-negative manner.
A modest height difference of at least 1 SD was observed between P1 (at age 3.4 years) and
her father [Fig. 1(a)], both of whom carried the same heterozygous dominant-negative GHR
c.964dupC; the GHR c.964dupC status of paternal family members who were short statured
(height SD, 22.07 to 24.4) are not known. Variations in height among subjects carrying the
same mutation are commonly observed. We previously reported, for example, that subjects
carrying the homozygous GHR c.618+792A.G splicing mutation, had height SDs from 23.3
to26.0 associated withmild to severe GHI phenotypes, and, for this splicing defect, the range
could be explained, in part, by variations in splicing efficiencies [19, 20]. Mechanism(s) to
explain the height variations in subjects carrying the same dominant-negative GHR
frameshift mutation remain to be fully elucidated, although penetrance of the heterozygous
mutation is likely to be a key contributing factor.
For two of the three GHR variants (c.964dupG and c.920_921ins14) reported, the JAK2
binding domain, Box1, is intact, whereas Box1 is lost in the c.945+2T.C variant. All three
truncations also remove the intracellular tyrosines that are required for recruiting and
docking of STAT5B [21]. Our functional studies for variants c.964dupG and c.920_921ins14 in
HEK293 cells support the hypothesis that these variants have dominant-negative effects and
are most likely the cause of GHI in our patients. When either one of the variants was
coexpressed with WT GHR (to recapitulate the heterozygous state in our patients), there
was a substantial reduction in phosphorylation of STAT5 [Fig. 4(a) and 4(b)]. Moreover, the
STAT5B-mediated transcriptional activities were reduced when themutant was coexpressed
with the WT GHR, supportive of dominant-negative effects [Fig. 4(c)]. For the c.945+2T.C
variant, the loss of exon 9, confirmed by RT-PCR of GHR mRNA, generated a truncated
protein identical to the two previously reported dominant-negative splicing variants, c.876-
1G.C and c.945+1G.A [12–14].
In summary, our patients carrying dominant-negative, heterozygous GHR mutations
presented with milder phenotypes compared with patients with classical homozygous,
autosomal-recessive GHI. The evidence suggests that this is due, in part, to the presence of
predicted 25%WTGHRhomodimers.WhenWTGHR forms a heterodimerwith the truncated
mutant GHR, downstream signaling and transcriptional activities are significantly blunted,
measured by relative pGHRE-LUC activities. The data are mean 6 standard error of the
mean of at least three experiments. The results of mutant only (c.964dupG or
c.920_921ins14) or WT + mutant cotransfections were compared with WT. *P , 0.01,
**P , 0.001.
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supporting dominant-negative effects exerted by the mutant variants. A combined therapy
with rhGH plus rhIGF-I appears to be an effective treatment option, with some response seen
in patients receiving rhIGF-I or rhGH alone. The possibility of heterozygous mutations in the
GHR intracellular domain should be considered in patients presenting with low IGF-I
concentrations and growth phenotypes less severe than seen in classical GHI syndrome.
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20. David A, Camacho-Hübner C, Bhangoo A, Rose SJ, Miraki-Moud F, Akker SA, Butler GE, Ten S,
Clayton PE, Clark AJ, Savage MO, Metherell LA. An intronic growth hormone receptor mutation
causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity
phenotypes. J Clin Endocrinol Metab. 2007;92(2):655–659.
21. Derr MA, Fang P, Sinha SK, Ten S, Hwa V, Rosenfeld RG. A novel Y332C missense mutation in the
intracellular domain of the human growth hormone receptor does not alter STAT5b signaling: re-
dundancy ofGHR intracellular tyrosines involved in STAT5b signaling.HormRes Paediatr. 2011;75(3):
187–199.
358 | Journal of the Endocrine Society | doi: 10.1210/js.2016-1119
